Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ocadusertib by Eli Lilly and Co for Rheumatoid Arthritis: Likelihood of Approval
Ocadusertib is under clinical development by Eli Lilly and Co and currently in Phase II for Rheumatoid Arthritis. According to...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Ocadusertib?
Ocadusertib is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Rheumatoid Arthritis....
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Ocadusertib?
Ocadusertib is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Rheumatoid Arthritis....